Posted on

TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PHASE 2A STUDY AT THE UNIVERSITY OF FLORIDA

San Diego, California – August 24, 2021 – Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for over-eating disorders.  The training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients.

Tryp believes that both pharmaceutical and psychological processes will play a synergistic role to determine outcomes for TRP-8802, an oral formulation of synthetic psilocybin.  Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect.  Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders conducted at the University of Florida with Jennifer Miller, M.D.  Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.

Commenting on the recent psychotherapy training, Jesse Dallery, Ph.D., Director of the Behavioral Health and Technology Research Clinic and Professor in the Department of Psychology at the University of Florida, said, “Establishing definitive guidelines and training for the psychotherapy portion of psychedelic therapies is essential to minimizing variability and optimizing the patient experience.  I was thoroughly impressed with the rigor and scientific basis of the training provided by Fluence for our upcoming study with Tryp Therapeutics and look forward to initiating our work with patients later this year.”

Tryp Therapeutics, Fluence, and the University of Florida have collaborated to create a comprehensive training manual for the psychotherapy portion of Tryp’s psychedelic treatment regimen that will be adapted for subsequent clinical trials in fibromyalgia and other chronic pain indications.

“We continue to be amazed by the complexity of neural networks and the array of biological and behavioral factors that influence the healthy functioning of the brain and body,” said Jim Gilligan, Ph.D., President and Chief Science Officer of Tryp Therapeutics.  “Our partners at the University of Florida have shown tremendous commitment to the effective administration of psychotherapy for our upcoming Phase 2a clinical trial, and Fluence continues to be an exceptional partner for the design and implementation of this important component of our therapies.  The completion of this psychotherapy training marks a significant milestone for Tryp, as it remains an integral part of our novel treatment.”

 

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and over-eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.  For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:
Joe Green
Edison Group
investors@tryptherapeutics.com

Media Inquiries:

Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

OPTIMI HEALTH CLEARS FINAL BASE SHELF PROSPECTUS

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC (GLOBE NEWSWIRE – August 18, 2021) – Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has filed and received a final receipt for a short form base shelf prospectus (the “Final Shelf Prospectus“) with the securities commissions in each of the provinces and territories of Canada, except Québec.

The Final Shelf Prospectus allows the Company to offer and issue up to $100,000,000 of common shares, warrants, subscription receipts, units, or any combination of such securities (collectively, the “Securities“) during the 25-month period that the Final Shelf Prospectus is effective. The Securities may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of sale, which will be set forth in any one or more prospectus supplement(s) filed in connection with any such distribution(s).

Optimi CEO, Mike Stier, stated, “while the Company has no immediate intention to undertake an offering, this Final Shelf Prospectus allows the Company to maintain financial flexibility as we advance our business objectives and goals.”

The Securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Securities in any State or jurisdiction in which such offer, solicitation or sale would be unlawful.

A copy of the Final Shelf Prospectus is available under the Company’s profile on SEDAR (www.sedar.com).

On Behalf of the Board of Directors

Optimi Health Corp.

Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations

Email: investors@optimihealth.ca

Phone: +1 (778) 930-1321

Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward-looking statements, including regarding the development of the Company’s business, potential distributions pursuant to the Final Shelf Prospectus and the filing of one or more prospectus supplements. These forward-looking statements are provided as of the date of this news release, and reflect predictions, expectations or beliefs regarding future events based information currently available to the Company. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including, but not limited to, the assumption that required approvals of any distribution proposed under the Final Shelf Prospectus and any supplement thereto will be obtained in a timely manner; that general economic and business conditions will not change in a materially adverse manner; and that the Company will be able to raise funds on reasonable terms. Although management considers these assumptions to be reasonable based on information available to them, they may prove to be incorrect. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions on which they are based do not reflect future experience. We caution readers not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. These risk factors may be generally stated as the risk that the assumptions and estimates expressed above do not occur, but specifically include, without limitation, risks relating to: general market conditions; the Company’s ability to secure financing, on favourable terms, pursuant to the Final Shelf Prospectus and any prospectus supplements; and the additional risks described in the Final Shelf Prospectus and the Company’s Annual Information Form, and other disclosure documents filed by the Company on SEDAR. The foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on behalf of the Company, except as required by law.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

Posted on

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug Candidates

TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Patent Cooperation Treaty (“PCT”) has published three patent applications, covering a range of Mindset’s Family 1 and Family 2 compounds, under the publication numbers: WO/2021/155467, WO/2021/155468, and WO/2021/155470.

With a priority date of more than 18 months ago, the patent applications cover a comprehensive range of novel diverse proprietary compounds designed to deliver superior therapeutic benefits to psilocybin with lower overall metabolic and safety liability and more predictable duration of action, along with their related synthetic process methods, potential compositions, formulation methods and therapeutic uses. The applications include novel prodrug, conjugates, deuterated and non-deuterated derivatives of psilocin, as well as its side-chain restricted analogs.

“The publication of our PCT patent applications reaffirms the novelty of our approach and first-to-file advantage,” said James Lanthier, CEO of Mindset. “We continue to run in vitro and in vivo tests on these patent-pending compounds to further validate their superior efficacy and safety profile.”

Mindset’s Family 1 compounds leverage state-of-the art modern drug design using conjugated and deuterated psilocybin and psilocin design strategies to improve on psilocybin’s potential toxicity and pharmacokinetics profile. Mindset’s Family 2 compounds are next-generation psilocybin and psilocin drug candidates optimized for in-clinic settings. The Company has run a battery of highly specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

To watch a video of Mindset’s CEO discuss the announcement in greater detail, please visit: https://youtu.be/SPx3KQB27Fw.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

OPTIMI ANNOUNCES FILING OF INTERIM FINANCIAL STATEMENTS AND MD&A

VANCOUVER, BC – (August 13, 2021) – Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), announces that it has filed its condensed interim consolidated financial statements and related management discussion and analysis for the period ended June 30, 2021, the documents can be found under the Company’s profile at www.sedar.com.

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.

Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations

Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

 

Posted on

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug Candidates

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug Candidates

TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Patent Cooperation Treaty (“PCT”) has published three patent applications, covering a range of Mindset’s Family 1 and Family 2 compounds, under the publication numbers: WO/2021/155467, WO/2021/155468, and WO/2021/155470.

With a priority date of more than 18 months ago, the patent applications cover a comprehensive range of novel diverse proprietary compounds designed to deliver superior therapeutic benefits to psilocybin with lower overall metabolic and safety liability and more predictable duration of action, along with their related synthetic process methods, potential compositions, formulation methods and therapeutic uses. The applications include novel prodrug, conjugates, deuterated and non-deuterated derivatives of psilocin, as well as its side-chain restricted analogs.

“The publication of our PCT patent applications reaffirms the novelty of our approach and first-to-file advantage,” said James Lanthier, CEO of Mindset. “We continue to run in vitro and in vivo tests on these patent-pending compounds to further validate their superior efficacy and safety profile.”

Mindset’s Family 1 compounds leverage state-of-the art modern drug design using conjugated and deuterated psilocybin and psilocin design strategies to improve on psilocybin’s potential toxicity and pharmacokinetics profile. Mindset’s Family 2 compounds are next-generation psilocybin and psilocin drug candidates optimized for in-clinic settings. The Company has run a battery of highly specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

To watch a video of Mindset’s CEO discuss the announcement in greater detail, please visit: https://youtu.be/SPx3KQB27Fw.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run Testing On Dashboard

Proprietary computer vision technology will provide the Ehave Dashboard and Ehave Medical App with the ability to extract information about changes in light absorption on an individual’s facial skin that is reflective of their physiological condition

Contactless Health Screening

MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has licensed AI technology from Vastminz as another tool to bring the Ehave Dashboard and Ehave Medical App to market. The AI technology to be included in the Ehave Dashboard and Ehave Medical App leverages years of research in artificial intelligence and computer vision to develop solutions that can perform tasks remotely without physical contact. More specifically, the computer vision technology will provide the Ehave Dashboard and Ehave Medical App with the ability to identify an individual’s physiological condition, such as Heart Rate, Heart Rate Variability (HRV), Respiration Rate, Oxygen Saturation Level, and other vital statistics. These changes in physiological condition will be identified by extracting information about changes in light absorption on an individual’s facial skin. The changes are captured within the RGB pixel values of camera frames and converted into various physiological vitals utilizing Vastmindz proprietary AI.

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/703f0a17-ad16-4c60-a9cb-585b4c8aa977

The Ehave Dashboard is a data driven platform developed to provide better communication among medical practitioners and health care providers., while also allowing individuals to have more control over their health. The cloud-based platform delivers critical features and capabilities to healthcare providers, all while enabling seamless integrations with electronic health records (EHRs), vaccine passports, and communication with providers. The aggregation of data and information into one application has proven effective in streamlining the health process for patients, researchers, and clinical providers. The AI powering the Ehave Dashboard is designed to alter itself when it accesses new data. By accessing the new data, the dashboard “learns.” Ehave’s collaboration with clinicians and researchers typically prompts this ability to improve using an objective of minimal error. This allows the system to comprehend which efforts are successful and increase the likelihood of using similar steps in the future.

Ben Kaplan, CEO of Ehave, said, “The growing capabilities and offerings of our Ehave Dashboard and Ehave Medical App allow us to power more remote care around the world. This not only gives individuals the ability to take their personal health journey to an entirely different level, it allows Ehave to do the heavy lifting as far as trustworthy data capture and transmission.” Mr. Kaplan continued, “This will allow our clinician and research partners to focus more on their specific application or therapeutic area, as well as help to democratize healthcare by enabling better outcomes with more cost-effective approaches.”

The Ehave Dashboard and Ehave Medical App utilize privacy-protecting technology to link clinical trial data using its Dashboard and AI to health data from various sources, including wearables, lab reports, and doctor and hospital visits. the Ehave Dashboard and Ehave Medical App have evolved into an ecosystem allowing an individual to take control of his or her mental health healing with an overall full snapshot of their entire healthy by collecting and organizing all data. Both the Ehave Dashboard and the Ehave Medical App allow individuals to own and share their health data in a secure and private environment. Providing data integrity and patient privacy gives patients the option to share their medical data with medical providers, research organizations, and pharmaceutical companies conducting clinical trials to better understand the treatments and experiences of patients with psychiatric and substance use disorders.

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Posted on

Professor Sammis takes Sabbatical to Devote Significant Time Toward Developing Psilocybin and Cannabis Intellectual Property (IP) for Delic Labs

Vancouver, British Columbia – August 10, 2021 – Delic Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced Professor Glenn Sammis, Scientific Advisor of its subsidiary Delic Labs has been granted a full professorship at the University of British Columbia as a member  of the Chemistry Department. Professor Sammis has further taken a twelve-month sabbatical from the University and will be devoting his time to working closely with Dr. Markus Roggen in developing intellectual property (IP) for Delic Labs’ cannabis and psilocybin research. Delic Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Delic Labs serves as the engine for the DELIC platform, conducting research and developing innovative product lines and intellectual property (IP), including psilocybin vaporization technology for future distribution across the Company’s physical footprint and licensed psychedelic wellness clinics in the United States.

“It is a great honor to earn a full-time professorship in chemistry with the University of British Columbia,” said Delic Labs Scientific Advisor Professor Glenn Sammis. “I am excited to spend the coming months of my sabbatical conducting intensive research alongside Dr. Roggen as we build out valuable IP in the burgeoning cannabis and psychedelic medical spaces. Our unique and early testing of lesser-known compounds and practices will give us a first-mover advantage in the medical psychedelic space.”

Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics,  metabolomic identification and process optimization. DELIC Labs is one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. DELIC Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world. DELIC Labs is applying for a Dealer’s License, and intends to eventually commercialize its psilocybin research and associated intellectual property (IP).

Dr. Sammis started his chemical education at Stanford University, receiving B.Sc. in Chemistry with Honors and Distinction in 1999. He then joined Prof. Eric Jacobsen at Harvard University as an NSF Predoctoral fellow and obtained a Ph.D. in Chemistry in 2004. After, he moved to Princeton University for a two-year NIH postdoctoral fellowship with Prof. Erik Sorensen. Dr. Sammis is now a Full Professor at the Chemistry Department at the University of British Columbia. He has built an internationally recognized research group working on the development of novel synthetic methods for the preparation of natural products and pharmaceuticals.

About Delic Labs (formerly Complex Biotech Discovery Ventures Ltd.)

Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

Investor Relations Contact

Daniel Southan-Dwyer

Corporate Development

dsd@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, information concerning listing on the Canadian Securities Exchange, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following: the ability to consummate the Proposed Transaction; ‎the ability to ‎obtain requisite regulatory and securityholder approvals and the satisfaction of ‎other conditions to the ‎consummation of the Proposed Transaction on the proposed terms and schedule; the ability to ‎satisfy the ‎conditions to the conversion of the Subscription ‎‎Receipts (as defined in the Previous Press Release); the potential impact of the announcement or consummation of the Proposed Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Proposed Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN UNITED STATES

Posted on

Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families

Mindset has identified several potential leads across its psilocybin/psilocin and DMT/5-MeO-DMT analogs that demonstrate superior efficacy, safety and shorter duration of action

‍

Toronto, Ontario– August 10, 2021 – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF)(“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that compounds from its Family 2, comprised of novel psilocybin/psilocin analogs, and Family 4, comprised of novel DMT/5-MeO-DMT analogs, have demonstrated superior efficacy, safety and shorter duration of action in head-to-head preclinical comparisons with their reference drugs.

“The improvement in duration and efficacy/safety of our next generation compounds has meaningful implications for psychedelic-based therapy in the clinic. These improvements could potentially offer a scalable approach for psychiatrists as they manage dosing and treatment strategies for patients suffering from mental illness,” said James Lanthier, CEO of Mindset.

“Initial in vitro screening indicated that our novel Family 2 compounds demonstrated 5-10 times the effect size as psilocin on human 5-HT2A receptors, which we were able to verify through in vivo mouse head twitch assays. Additionally, in vitro assays suggested that several of these compounds metabolized at least twice as rapidly as psilocin, while in vivo rodent studies indicated the half-life of key Family 2 compounds were less than half than that of psilocybin,” stated Joseph Araujo, Chief Scientific Officer of Mindset. “For our Family 4 compounds, in vitro studies indicated greater effect size at the human 5-HT1A, 5-HT2A, and 5-HT2C subtype receptors compared to DMT and 5-MeO-DMT. Furthermore, results suggested that the half-life of our compounds range from 7-90 minutes, providing a broad range of potential duration effects. Head twitch and behavioral assays showed increased serotonergic effects of our DMT and 5-MeO-DMT analogs. Based on these Family 4 results, our compounds exhibit a broad range of pharmacological diversity that differentiates this short-acting family from Mindset’s psilocybin-inspired families.”

Mindset’s Family 2 compounds are next-generation psilocybin and psilocin analogs optimized for in-clinic settings and Mindset’s Family 4 compounds are DMT and 5-MeO-DMT inspired drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

To watch an interview of the Company’s management team discuss this announcement in greater detail, please visit: https://youtu.be/d-NuUlvGmuI.

For more information, please contact:

Investor Contact:

Allison Soss/Tim Regan

KCSA Strategic Communications

Email: MindSet@kcsa.com

Phone: 212-896-1267/347-487-6788

Company Contact:

James Lanthier, CEO

Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development

Email: jatkinson@mindsetpharma.com

Phone: 416-479-4094

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

‍Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

‍NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team

Dr. Weingardt, a clinical psychologist and previously a Senior Clinical Director at Pear Therapeutics will guide MINDCURE’s digital therapeutics technology (DTx) platform, iSTRYM, through near-term commercial deployment

VANCOUVER, BC, Aug. 10, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased today to welcome Dr. Ken Weingardt, CEO of Audacious Digital Health, as a consulting Senior Clinical Technology Advisor.

Dr. Weingardt will work with the MINDCURE team to take the minimum viable product (MVP) version of iSTRYM, the Company’s digital therapeutics platform, to clinical excellence in both commercial deployment and design. He will focus on the Company’s science-based, evidence-backed approach and guide iSTRYM as we accelerate toward near-term commercial deployment.

As forecast, iSTRYM is currently on schedule and on budget, with MVP deployment in Q3 2021 and commercial deployment Q1 2022.

“Adding Ken to our team is a hallmark moment. We are in the early days of this fast-growing psychedelics market and are proud that Ken chose to work with MINDCURE,” said Kelsey Ramsden, President & CEO, MINDCURE. “I’m honoured and excited to show what we will achieve together. I believe that vision, teamwork, and speed of execution are the keys of every disruptive business that delivers on its strategy and drives results for its customers and its investors.”

A clinical psychologist with 20 years of experience working at the intersection of technology and behavioural health, Dr. Weingardt was most recently the Director of Clinical Programs at Woebot Health and a Senior Clinical Director at Pear Therapeutics. In July of this year, Woebot Health closed a $90 million Series B round, and Pear Therapeutics recently announced plans to go public in a $1.6 billion SPAC deal. At Pear, Dr. Weingardt worked with product, engineering, data science, and regulatory teams in developing FDA-approved prescription digital therapeutics for psychiatric disorders. In his career to date, he has led the development and implementation of digital behavioural and mental health technologies globally.

“I’m very excited to join MINDCURE as an advisor,” said Dr. Ken Weingardt. “This company is among the first to develop a digital therapeutic specifically designed to support the process of psychedelic-assisted therapy. I am delighted to advise the team as they leverage innovative technologies to potentially reduce symptoms, improve quality of life, and support transformation and healing.”

iSTRYM is a first-of-its-kind software application that optimizes the healing journey for both patients and clinicians — before, during, and after therapy sessions. By bringing together and building proprietary technological solutions, iSTRYM offers therapists global, evidence-backed treatment protocols, in-session psychedelic-informed tools, customizable dashboards, integration plans, insights into patient journeys, and real-time assessments for personalized client care.

iSTRYM is set up to operate like a standard SaaS platform. Clinics who onboard with the technology pay a set-up fee for training, and an ongoing fee determined by the size of clinic and number of therapists. iSTRYM provides clinics with standard treatment protocols and serves as a distribution arm for treatment protocols from other brand name providers and research institutions. MINDCURE intends to scale iSTRYM globally, whenever and wherever mental health can be served by a quantified and personalized care program.

Developing the distribution network of content and care protocols for psychedelic drugs will allow MINDCURE to create value at all levels of the value chain: client, clinic, protocol developer, and drug developer.

iSTRYM will be available to a select number of clinics throughout North America in Q3 2021. The software will be launched broadly and commercially to clinics in Q1 2022. The launch will initially target psychedelic centers and is planned to expand to integrated clinics, both traditional and psychedelic, and eventually the broader mental health market. The company intends to file for FDA approval under the software as a medical device (SaMD) pathway, streamlining reimbursement and providing validation as a therapeutic intervention.

About Dr. Ken Weingardt

Dr. Weingardt is a clinical psychologist with 20 years of experience working at the intersection of technology and behavioral health. As an Associate Professor at Northwestern Feinberg School of Medicine he served as the Scientific Director, Center for Behavioral Intervention Technologies (CBITS), where he worked with researchers and clinicians to develop and evaluate digital therapeutics for behaviour health. Prior to this, he held an appointment as a Consulting Associate Professor in in the Department of Psychiatry and Behavioural Sciences at Stanford University School of Medicine. In addition, he has served in a variety of national leadership roles in the US Department of Veterans Affairs (VA), including the National Director for Mental Health Web Services, where he led a team that was responsible for all of the VA mental health web assets including the patient portal. In his career to date, has led the development and implementation of digital behavioural and mental health technologies globally.

On another note, the Company also announces that it has granted an aggregate of 25,000 stock options under its incentive stock option plan (the “Plan”) to employees of the Company. The stock options are exercisable at a price of $0.405 and subject to the terms of the Plan.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business.  Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, performance or achievements contemplated by forward-looking statements made may be materially different from the results anticipated or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; or that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, and support transformation and healing.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Jonathan L. Robinson CFA, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

OPTIMI HEALTH UPDATES LAUNCH OF ONLINE FUNCTIONAL MUSHROOM SALES

VANCOUVER, BC (August 10, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, announced today that preparations for a fourth quarter launch of online sales featuring a full lineup of functional mushroom capsules plus a vegan protein + mushroom formulation are well underway with further information coming soon at www.optimilife.com.

Dane Stevens, Chief Marketing Officer of Optimi Health notes, “As we near the upcoming launch of our online sales we are excited about transforming Optimi into a vertically integrated and actively revenue generating company. It’s important for both Optimi and our shareholders to utilize new-found revenues to spur value creation and help fund our ongoing initiatives. We remain committed to driving innovation, executing our upcoming clinical trials, and ultimately growing our footprint throughout North America and beyond. An aggressive product sales strategy has long been a part of our blueprint to achieve these goals.”

“A big part of our commitment to excellence includes intensively utilizing the fruiting body of the mushroom.” Stevens continues, “Our decision to focus on this important ingredient means consumers who choose Optimi will be guaranteed products rich in the valuable beta glucans that underpin the benefits of the Lion’s Mane, Chaga, Turkey Tail, Reishi and Cordyceps strains that make up our unique Optimi formulas.”

Concurrently in Q4 of this year, Optimi plans to strategically launch a dedicated sales channel on a proven direct-to-consumer platform through a partnership with VitaSave (https://www.vitasave.ca). At launch, the business will focus on the Canadian market with the intention of entering the US market in 2022. Optimi will continue to develop additional product innovations to complement and expand upon the launch offerings.

Additionally, as part of a dedicated campaign to ensure go-to-market launch success, Optimi has begun working with Colony Digital, a subsidiary of online publishers Daily Hive, for the roll-out of upcoming marketing initiatives and consumer awareness strategies.  To further support the launch, Optimi has retained the Vancouver office of Citizen Relations to drive enhanced awareness across the Canadian consumer market landscape.

Optimi’s mission is to use functional mushrooms to optimize the whole body and mind. These products are a significant part of the Company’s vision to help build a better future for everyone, and to achieve this by helping individuals maximize their potential. Mushrooms have been an important ingredient in eastern medicine for thousands of years. North American consumers are becoming increasingly better informed and seeking out the many amazing benefits mushrooms can bring to their supplement routines. Optimi is ready to help the growing number of enthusiastic adopters by delivering the best all-natural formulations for both body and mind.

Interested consumers can sign-up for launch information and pre-launch offers at https://optimilife.com/.

The following products will be available at launch:

  • Vegan Protein + Mushroom Formulation: Vanilla-flavoured formulation of 5 mushrooms with a delicious vegan protein powder. Provides antioxidants to protect against cell and tissue damage and to help strengthen the immune system. Available in 20 or 30 serving sizes.
  • Optimi Formulation Capsules: Daily dose of Cordyceps, Lion’s Mane, Chaga, Reishi and Turkey Tail delivers functional benefits for the whole body and mind, offering immune support and age-fighting antioxidants. 30-day supply.
  • Defense Formulation Capsules: Chaga delivers age-fighting antioxidants, supports immunity and has anti-inflammation benefits. 30-day supply.
  • Perform Formulation Capsules: Cordyceps delivers energizing compounds, reduces fatigue and improves oxygen utilization to help users go harder and longer. 30-day supply.
  • Longevity Formulation Capsules: Reishi formulation increases resistance to stress and adds the mood boosting benefits of Longevity. 30-day supply.
  • Immunity Formulation Capsules: Turkey Tail formulation assists and supports the immune system to help protect against disease and illness. 30-day supply.
  • Mindful Formulation Capsules: Lion’s Mane, a brain boosting supplement to enhance cognitive function, memory, and mind clarity. 30-day supply.

“Optimi is highly focused on designing products that will allow consumers to capture the amazing benefits of mushrooms in easy-to-use ways” adds Optimi’s Stevens. “We believe our exceptional capsules and vegan protein formulations are actually a major step forwards in bringing superior functional mushrooms into the mainstream across North America. We are particularly enthusiastic regarding the use of the high-value fruiting body ingredients we have created using only the finest high temperature, highly filtered, naturally mineralized water process to ensure our customers are guaranteed the maximum benefit from every product we produce.”

On Behalf of the Board of Directors,
Optimi Health Corp.

Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.